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1.1. Urotensin II receptor agonists
Urotensin II (UII) receptor agonists are of signiﬁcant inter-
est in drug discovery because of the potential role of UII in
numerous diseases including hypertension, heart failure,
renal failure and diabetes. Many (but not all) of the UII
agonist and antagonist examples in the literature are
peptidic in nature, so there remains a need for potent and
selective, low molecular weight ligands to further examine
the biology and pharmacology of the UII system. Recent
work has sought to address this need through exploration
of the SAR around a series of low molecular weight UII
agonists, typiﬁed by FL104 (1), the most potent UII
agonist reported to date.1
A small library of 30 compounds was synthesised as single-
tons in dichloromethane solution from sets of ten carb-
oxylic acids and three amines, and utilising solid phase
coupling reagents. Compounds were monitored by NMR
and puriﬁed by small-scale parallel extractions followed
by ion exchange chromatography as necessary. The com-
pounds produced around the chemotype (1) were tested
for their agonistic properties at human UII receptors using
the functional R-SATTM assay. For control of UII recep-NH
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carinic m3 receptor as a negative control.
From this library, several potent agonists of UII were iden-
tiﬁed as evidenced by their UII receptor activities using the
R-SATTM cell-based assay. From the assay it was found
that 13 compounds exhibited EC50 values between 130
and 870 nM, and that conjugated amides (e.g., compound
2, EC50 = 130 nM) in general were better than aliphatic
amides.1.2. New rubella virus inhibitors derived from 4-alkylamino-
6-(2-hydroxyethyl)-2-methylthiopyrimidines
Rubella virus (RV) is the only member of the Rubivirus
genus of the Togaviridae and it is characterised by a posi-
tive-sense single stranded RNA genome consisting of 9762
nucleotides. Symptoms of the virus are a scarlatiniform
rash, cervical lymphadenopathy and mild constitutional
symptoms, but in older children and adults, especially wo-
men, it may be more severe, with purpuric rash being seen
for example.
Rubella was the ﬁrst virus demonstrated to be teratogenic.
Infection during the ﬁrst 12 weeks of pregnancy results in
congenital infection and/or miscarriage in 80–90% of cases.
The development of live and attenuated vaccines and the
expansion of vaccination strategies since 1970 have
reduced, but not eradicated, the incidence of congenital
rubella syndrome (CRS). If the viral infection leading to
CRS occurs in the ﬁrst part of pregnancy, particularly in
women without speciﬁc immunological protection, anoma-
lies observed include nerve deafness, and cardiac anoma-
lies, with late complications including diabetes, thyroid
disease, and growth hormone deﬁciency. Although natural
and semisynthetic polysaccharides, and acylated 1,2,4-tri-
azole derivatives, for example, show inhibitory eﬀects
against RV, speciﬁc therapies to prevent CRS are currently
unavailable. There remains a need to develop new antiviral
agents, and recent work has disclosed a series of new
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the aim to improve their antiviral potency and pharmaco-
logical proﬁle.2N
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5The library chemotypes (3 and 4) were prepared through
the use of solution phase parallel synthesis. Synthesis pro-
ceeded via the tosylate (5) and utilized a Buchi Syncore to
produce a small library of 19 compounds. The antiviral
activity of the synthesised compounds was evaluated in
Vero cells starting from the highest non-cytotoxic concen-
tration which did not aﬀect any parameter (cell morpho-
logy, viability and growth) considered in 100% of the
cells. After virus adsorption, the viral inoculum was
removed, cell monolayers were washed three times with
buﬀer and incubated in the presence or absence of a two-
fold dilution curve of the compounds. Viral inhibition
was evaluated by plaque assay after a single cycle of virus
multiplication. From this screening eﬀort, it was found that
antiviral activity did not vary markedly between com-
pounds in the series, ranging over one order of magnitude.
Amongst the best from the library was compound 6, exhi-
biting an IC50 value of 13.5 lM and represents a reasonable
starting point for further medicinal chemistry.N
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2.1. Solid-phase synthesis
Three generations of peptoid-based dendrimers have been
synthesised by solid-phase methods. Using N-Fmoc–N-(6-
N0-Fmoc-aminohexyl)-glycine as both the initiator core
and the monomer unit, the approach oﬀers an unusual
dendrimeric periphery composed of both secondary and
primary amines. The third generation compound proved
to be an eﬃcient mediator of transfection while displaying
minimal cytotoxicity.3
The synthesis of a new peptidomimetic structure, the
alkene dipeptidosulphonamide isostere, has been described.The synthesis was based on a cross metathesis reaction
between two allylic building blocks, both in solution and
on the solid phase. This method was also applicable to
the solid phase synthesis of alkene dipeptide isosteres.4
2.2. Solution-phase synthesis
Practical and eﬃcient solution-phase parallel synthesis of
spiroisoxazolinohydantoins under mild conditions has
been developed. This spiroisoxazolinohydantoin skeleton
possesses three diversity points, and the key intermediate,
exo-methylenehydantoin bearing two positions of diversi-
ﬁcation, is prepared via a one-pot synthetic route from
N-substituted methyl ester serine. Employing various alkyl
halides, isocyanates, and oximes, this chemistry was
applied to the generation of an 18-member demonstration
library with high yield, high purity and excellent
regioselectivity.5
A focused library of novel 2-unsubstituted 4-(substi-
tuted)anilinothieno[2,3-d]pyrimidines has been synthesised
through the chlorination of the corresponding 2-unsub-
stituted-thieno[2,3-d]-pyrimidin-4-ones, followed by the
nucleophilic displacement of the 4-Cl group with a variety
of anilines. All four steps of this synthesis towards
geﬁtinib analogues involve microwave irradiation (MWI)
and the entire synthesis requires only 2 hours for
completion.62.3. Scaﬀolds for combinatorial libraries
No papers this month.
2.4. Solid-phase supported reagents
A novel one-pot solvent-free synthesis of 1,3,4-oxadiazoles
and 1,3,4-thiadiazoles by condensation of acid hydrazide
and triethyl orthoalkanoates under microwave irradiation
has been reported. This green protocol was eﬃciently cata-
lysed by solid-supported NaﬁonNR50 and phosphorus
pentasulphide in alumina (P4S10/Al2O3) with excellent
yields.7
Polymer-supported chiral 1,2-diamines have been prepared
by two methods including (1) chemical modiﬁcation of a
Merriﬁeld-type resin with a chiral 1,2-diamine and (2) poly-
merisation of a 1,2-diamine monomer. The polymeric com-
plex formed by the polymer-supported 1,2-diamine and
RuCl2-BINAP was used for the asymmetric hydrogenation
of aromatic ketones to aﬀord the corresponding secondary
alcohols in quantitative yields with enantioselectivities up
to 99% ee in the asymmetric hydrogenation.8
2.5. Novel resins, linkers and techniques
The use of hydroxythiophenol (Marshall) resin to synthe-
sise hydroxamic acids from carboxylic acids and its appli-
cation to convert a library of 14 discrete aliphatic and
aromatic carboxylic acids including N-protected amino
acids to their corresponding hydroxamic acids in good
yields is described.9
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Molecular chaperones, such as Hsp70 and Hsp90, are
responsible for a variety of protective, anti-apoptotic
functions. Interesting lead candidates for Hsp70 share a
dihydropyrimidine core; and an exploratory compound
collection was assembled by performing a Biginelli cyclo-
condensation at the terminus of a resin-bound b-peptide.
Liberation from solid support yielded peptide-modiﬁed
dihydropyrimidines and, within this series, compounds that
alter the ATPase activity of Hsp70 and its bacterial ortho-
logue, DnaK were discovered.10
A library of anilinoanthraquinone derivatives has been
synthesised by the parallel Ullmann coupling reaction of
bromaminic acid with aniline derivatives in solution using
a compact parallel synthesiser. The products were puriﬁed
by HPLC and evaluated as antagonists at mouse and
human P2Y2 receptors.
11
Structure–activity relationships were analysed within a
60-compound library of diverse yet simple compounds
prepared as histamine H3 antagonists. The libraries were
constructed with a variety of low molecular weight
pyrrolidines, selected from (R)-2-methylpyrrolidine, (S)-2-
methylpyrrolidine, and pyrrolidine.12
A recent report describes a study to ﬁnd small peptide sub-
strates for the important virulence factor of Yersinia pestis,
plasminogen activator, Pla. The method used to ﬁnd small
substrates for this protease is reported along with studies
examining the ability of these peptides to inhibit activity
of the enzyme. Through the use of parallel synthesis and
positional scanning, small tripeptides were identiﬁed that
are viable substrates for the protease.13
A combined approach for targeting RNA with novel, bio-
logically active ligands has been developed using a cyclic
peptide library and in silico modelling. This approach has
successfully identiﬁed novel cyclic peptide constructs that
can target bTAR RNA.14
The preparation and screening of a set of 55 pyridine di-
carbonitriles as potential prion disease therapeutics has
been reported. The library was analysed for binding to
human prion protein (huPrPC) by surface plasmon reso-
nance and for inhibition of the formation of its partially
protease resistant isoform PrPSc in mouse brain cells. A
total of 26 compounds were found to bind to huPrPC whilst
12 showed discernable inhibition of PrPSc formation, ﬁve
displaying EC50 values in the range 2.5–9 lM.15
Histone methylation is an epigenetic mark essential for gene
regulation and development. Peptide SPOT synthesis has
been used to study sequence speciﬁcity of the Dim-5
histone-3 lysine-9 methyltransferase reaction. Comparative
analyses of peptide arrays with wild-type and mutant
enzymes, are well suited to investigate the target speciﬁcity of
protein methyltransferases and study epigenetic crosstalk.16
Natural peptide products often contain N-methylated
backbones, and such a modiﬁcation plays a crucial rolein making natural peptides peptidase resistant and mem-
brane permeable. The ribosomal synthesis of N-methyl-
peptides by means of genetic code reprogramming has been
described. Two key technologies, a ribozyme-based de
novo tRNA acylation (ﬂexizyme) system and an E. coli
reconstituted cell-free translation (PURE) system, were
used in order to reassign arbitrarily chosen codons to Na-
methylated amino acids (Meaa). Using this combination,
the general structural requirements of ‘‘accessible” Meaa
were determined and their multiple incorporations into
the nascent peptide chain according to the assignments
made on mRNA was demonstrated, giving linear and
cyclic N-methyl-peptides in high purities. This platform
technology oﬀers a convenient tool for the construction
of N-methyl-peptide libraries, potentially leading to the
discovery of therapeutic peptides.17References
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